Skip to main content

Evidence-Based Supplement Research

Evidence-Based Supplement Research

Bifidobacterium lactis BLA80 and Reduced Upper Respiratory Infections

Doses used in studies

CFU/day: 5 billion (median 5 billion, IQR 5 billion–5 billion) — 2 studies

Time to effect

Median: 6 months · IQR 6 months–6 months · Range 6 months–6 months — Reported in 1 of 1 study

1 of 1 paper

Efficacy of Bifidobacterium lactis BLa80 in preventing early childhood eczema and respiratory infections via gut microbiome and immune modulation.
- 2026-05-28
- Clinical Trial
- Frontiers in nutrition 13
- - Ke Chen
  - Shanshan Jin
  - Yang Nie
  - Nianyang He
  - Haixia Chen
  - Jie Yuan
  - Xiaohui Li
  - Min-Tze Liong
- PubMed: 42293186
- DOI: 10.3389/fnut.2026.1727191
9 Insights on
- Reduced Upper Respiratory Infections
- High evidence
- Infants
Significantly reduced ... upper respiratory tract infections (19.4% vs. 42.5%, RR: 0.457, p < 0.001)
Effect
Beneficial
Effect size
Large
Significant
Yes
Dose
5 × 10^9 CFU daily